NASDAQ : ALDX
Aldeyra Therapeutics, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 0.5603 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 33.80M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 35.18M |
| Enterprise Value | -9.76M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 60.33M |
| Shares Outstanding | 60.33M |
| Shares Change (YoY) | +0.79% |
| Shares Change (QoQ) | +0.00% |
| Owned by Insiders (%) | 3.60% |
| Owned by Institutions (%) | 45.48% |
| Float | 48.95M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.89 |
| P/TBV Ratio | 0.87 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 4.91 |
| Quick Ratio | 4.67 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -16.95 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -49.48% |
| Return on Assets (ROA) | -22.70% |
| Return on Invested Capital (ROIC) | -27.63% |
| Return on Capital Employed (ROCE) | -63.52% |
| Weighted Average Cost of Capital (WACC) | 14.19% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$3.84M |
| Employee Count | 6 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.20 |
| 52-Week Price Change | -88.50% |
| 50-Day Moving Average | 1.13 |
| 200-Day Moving Average | 2.26 |
| Relative Strength Index (RSI) | 27.57 |
| Average Volume (20 Days) | 1,410,309 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 3.19M |
| Short Previous Month | 3.47M |
| Short % of Shares Out | 5.28% |
| Short % of Float | 6.51% |
| Short Ratio (days to cover) | 1.78 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -24.07M |
| Pretax Income | -23.05M |
| Net Income | -23.05M |
| EBITDA | -23.80M |
| EBIT | -24.07M |
| Earnings Per Share (EPS) | -$0.38 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 45.09M |
| Total Debt | 143,447 |
| Net Cash | 44.95M |
| Net Cash Per Share | $0.75 |
| Equity (Book Value) | 37.89M |
| Book Value Per Share | 0.63 |
| Working Capital | 37.72M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -22.02M |
| Capital Expenditures | -23,097 |
| Depreciation & Amortization | 266,104 |
| Net Borrowing | -15.30M |
| Free Cash Flow | -22.04M |
| FCF Per Share | -$0.37 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -0.79% |
| Shareholder Yield | -0.79% |
| Earnings Yield | -65.62% |
| FCF Yield | -66.86% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $6.60 |
| Price Target Difference | 1,031.69% |
| Analyst Consensus | Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |